- Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo(2013)
Authors: Daphné Benteyn, Sébastien Anguille, Sandra Van Lint, Carlo Heirman, An MT Van Nuffel, Jurgen Corthals, Sebastian Ochsenreither, Wim Waelput, Katrien Van Beneden, Karine Breckpot, et al.
- Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy(2012)
Authors: Sandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, Lode Goethals, Aurélie Disy, Daphné Benteyn, Joeri Pen, Aude Bonehill, Carlo Heirman, Karine Breckpot, et al.
Pages: 1661 - 1671
- mRNA: delivering an anti-tumor message?(2011)
Authors: Sandra Van Lint, Kris Thielemans, Karine Breckpot
Pages: 605 - 607
- Large double copy vectors are functional but show a size-dependent decline in transduction efficiency(2010)
Authors: Tomas J Bos, Sandra Van Lint, Carlo Heirman, Karin Vanderkerken
Pages: 37 - 40
- HIV-1 Lentiviral vector immunogenicity is mediated by Toll-Like Receptor 3 (TLR3) and TLR7(2010)
Authors: Karine Breckpot, David Escors, Frederic Arce, Lucienne Lopez, Katarzyna Karwacz, Sandra Van Lint, Marleen Keyaerts, Mary Collins
Pages: 5627 - 5636
- Dendritic cell-based immunotherapy in lung cancer
Authors: Dieter Stevens, Sandra Van Lint, Karim Vermaelen
- Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy
Authors: Perpetua U Emeagi, Sandra Van Lint, Cleo Goyvaerts, Sarah Maenhout, Anje Cauwels, Lain A McNeish, Tomas Bos, Carlo Heirman, Kris Thielennans, Joeri L Aerts, et al.
Pages: 1342 - 1352